BAL 30072
Alternative Names: BAL0030072; BAL30072Latest Information Update: 28 Aug 2018
Price :
$50 *
At a glance
- Originator Basilea Pharmaceutica
- Class Antibacterials; Monobactams; Pyridones
- Mechanism of Action Beta lactamase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Gram-negative infections
Highest Development Phases
- No development reported Gram-negative infections
- Discontinued Respiratory tract infections
Most Recent Events
- 28 Aug 2018 No recent reports of development identified for phase-I development in Gram-negative-infections(Combination therapy, In volunteers) in Switzerland (IV, Infusion)
- 28 Aug 2018 No recent reports of development identified for phase-I development in Gram-negative-infections(In volunteers) in Switzerland (IV, Infusion)
- 15 Aug 2016 BAL 30072 is still in phase I trials for Gram-negative-infections (In volunteers) in Switzerland (IV, Infusion)